The earnings call highlighted significant growth and successful product launches, particularly with EluPro, alongside improved gross margins and progress in litigation settlements. However, challenges remain with SimpliDerm's performance and ongoing litigation issues.

Company Guidance

During Elutia's Second Quarter 2025 earnings call, the company provided robust guidance centered on the continued success and expansion of their EluPro product. EluPro saw a remarkable 49% sequential growth this quarter, with active ordering from 161 hospital systems. The company's strategic focus is on increasing the number of hospitals under contract through VACs and GPOs, which directly drives revenue. EluPro now constitutes 68% of the BioEnvelope revenue, with expectations to end the year at a $20 million revenue rate. Elutia also highlighted the upcoming NXT-41 platform for breast reconstruction, targeting a $1.5 billion U.S. market, and emphasized their ongoing strategic opportunities aimed at enhancing their cash position and business development. Gross margin improvements were noted, with the BioEnvelope business achieving a 62.4% adjusted gross margin, up over 4 percentage points from the previous year.

EluPro Commercial Success

EluPro experienced 49% sequential growth this quarter, driven by 7 national GPO contracts and active ordering from 161 hospital systems. EluPro makes up 68% of BioEnvelope revenue, and sales per account are 130% higher compared to CanGaroo.

Awards and Recognition

Elutia received the Edison Award for Innovation in Medical Technology, two Medical Device Network Excellence Awards, and Dr. Michelle Williams won the Medical Device Innovator of the Year award.

BioEnvelope Revenue Growth

BioEnvelope revenue for the quarter increased by 33% year-over-year, reaching about a $14 million run rate, primarily driven by EluPro growth.

Litigation Progress

Elutia settled 97 out of 110 lawsuits stemming from a past product recall, significantly reducing future legal expenses and removing a strategic overhang.

Gross Margin Improvement

Adjusted gross margin increased to 62.4% for Q2, up from 58.4% a year ago, due to operational efficiencies and high margins in the cardiovascular segment.

Aziyo Biologics (ELUT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ELUT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-0.15 / -	-0.33	―	―	―
Aug 14, 2025	2025 (Q2)	-0.17 / -0.26	-1.14	77.19% (+0.88)
May 08, 2025	2025 (Q1)	-0.20 / -0.21	-0.75	72.00% (+0.54)
Mar 06, 2025	2024 (Q4)	-0.25 / -0.26	-0.66	60.61% (+0.40)
Nov 14, 2024	2024 (Q3)	-0.44 / -0.33	-0.5	34.00% (+0.17)
Aug 07, 2024	2024 (Q2)	-0.33 / -1.14	-0.65	-75.38% (-0.49)
May 09, 2024	2024 (Q1)	-0.41 / -0.75	-0.49	-53.06% (-0.26)
Mar 07, 2024	2023 (Q4)	-0.28 / -0.66	-0.38	-73.68% (-0.28)
Nov 13, 2023	2023 (Q3)	-0.55 / -0.50	-0.73	31.51% (+0.23)
Aug 14, 2023	2023 (Q2)	-0.29 / -0.65	-0.69	5.80% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ELUT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$2.15	$2.02	-6.05%
May 08, 2025	$1.99	$2.08	+4.52%
Mar 06, 2025	$2.55	$2.78	+9.02%
Nov 14, 2024	$3.83	$3.56	-7.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Aziyo Biologics, Inc. Class A (ELUT) report earnings?

Aziyo Biologics, Inc. Class A (ELUT) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).

What is Aziyo Biologics, Inc. Class A (ELUT) earnings time?

Aziyo Biologics, Inc. Class A (ELUT) earnings time is at Nov 17, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ELUT EPS forecast?

ELUT EPS forecast for the fiscal quarter 2025 (Q3) is -0.15.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing